Cushing Bethany, Jacob Benjamin, Low XinYi, McGlynn Sam, Horvath Ildiko, Vranka Martina, Sarkeala Tytti, Redmond Patrick
Royal College of Surgeons in Ireland School of Medicine, Dublin, Leinster, Ireland.
Royal College of Surgeons in Ireland Department of General Practice, Dublin, Leinster, Ireland.
HRB Open Res. 2025 Jun 25;8:71. doi: 10.12688/hrbopenres.14160.1. eCollection 2025.
Lung cancer is the leading cause of cancer-related mortality worldwide. Low-dose CT (LDCT) lung cancer screening (LCS) reduces lung cancer-specific mortality by 20%, yet participation remains low, often below 15%, compared with 60-75% for other cancer screening programmes. Barriers such as limited accessibility, stigma, fear of diagnosis, and misconceptions contribute to poor uptake, particularly among high-risk groups, including heavy smokers, ethnic minorities, and individuals from lower socioeconomic backgrounds. Various recruitment strategies-such as personalised invitations, media campaigns, and primary care referrals-have been implemented, but their effectiveness across different populations remains unclear. This umbrella review will synthesise evidence from systematic reviews to identify the most effective recruitment strategies for improving LCS participation.
This umbrella review will follow Joanna Briggs Institute guidelines and the PRIOR reporting framework. A systematic search of PubMed, Embase, Scopus, Web of Science, Cochrane Library, and systematic review registries will identify systematic reviews published before 31 October 2024. Eligible reviews must evaluate LCS recruitment strategies and report on at least one of the following: population reach, screening up take, adherence, patient experience, or implementation barriers. Quality will be assessed using AMSTAR 2, and overlapping primary studies will be mapped to prevent duplication. A narrative synthesis will categorise recruitment strategies, and a qualitative effectiveness ranking will summarise key findings.
Findings will inform LCS recruitment strategies in Europe, contributing to the EU4Health-funded EUCanScreen programme. This review will support efforts to improve uptake, reduce disparities, and enhance early detection and survival outcomes of lung cancer.
肺癌是全球癌症相关死亡的主要原因。低剂量CT(LDCT)肺癌筛查(LCS)可将肺癌特异性死亡率降低20%,然而与其他癌症筛查项目60%-75%的参与率相比,LCS的参与率仍然很低,通常低于15%。有限的可及性、耻辱感、对诊断的恐惧以及误解等障碍导致参与率低下,尤其是在高危人群中,包括重度吸烟者、少数民族以及社会经济背景较低的人群。已经实施了各种招募策略,如个性化邀请、媒体宣传和初级保健转诊,但它们在不同人群中的有效性仍不明确。本系统综述将综合系统评价的证据,以确定提高LCS参与率的最有效招募策略。
本系统综述将遵循乔安娜·布里格斯研究所指南和PRIOR报告框架。对PubMed、Embase、Scopus、Web of Science、Cochrane图书馆和系统评价注册库进行系统检索,以识别2024年10月31日前发表的系统评价。符合条件的综述必须评估LCS招募策略,并至少报告以下一项内容:人群覆盖范围、筛查参与率、依从性、患者体验或实施障碍。将使用AMSTAR 2评估质量,并绘制重叠的原始研究以防止重复。叙述性综合将对招募策略进行分类,定性有效性排名将总结主要发现。
研究结果将为欧洲的LCS招募策略提供参考,为欧盟4健康基金资助的欧盟肺癌筛查项目做出贡献。本综述将支持提高参与率、减少差异以及改善肺癌早期检测和生存结果的努力。